Navigation Links
Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
Date:9/4/2007

*Isis Now Has Two Drugs From Its Metabolic Disease Program In Clinical

Development

CARLSBAD, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today it has initiated a Phase 1 study of ISIS 325568, an antisense drug designed to improve blood glucose control in patients with type 2 diabetes by inhibiting production of the glucagon receptor (GCGR). GCGR is a receptor that binds glucagon, a hormone that opposes the action of insulin. The Phase 1 trial of ISIS 325568 is designed to assess the drug's activity, including its effect on liver glucose production, as well as safety and pharmacokinetic profiles, providing the opportunity to demonstrate proof-of-concept in this first human trial. The study is a randomized, placebo-controlled, dose-escalation study conducted in healthy volunteers.

"We are excited by the preclinical profile of ISIS 325568, a novel first-in-class drug that has demonstrated excellent glucose control and improved pancreatic function through a dual mechanism of action in insulin-resistant animal models. Furthermore, the favorable effects on GLP-1 that we have seen exceed those observed with DPP IV inhibitors, and there was no evidence of hypoglycemia or GI side effects. These preclinical findings suggest that ISIS 325568 could offer disease modifying effects and long-term disease control both as a single agent and in combination with other diabetes treatments," said Sanjay Bhanot, M.D., Ph.D., Vice President of Metabolic Diseases Research & Development, Isis Pharmaceuticals. "In addition to demonstrating safety and tolerability in this study, we will be closely monitoring a number of biomarkers that could provide
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Malvern initiates European user group meetings for chemical imaging
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... China Nepstar Chain Drugstore Ltd. (NYSE: NPD ) ... in China based on the ... board of directors has received a preliminary non-binding proposal ... , chairman of the board of directors of the ... vehicle wholly owned by Mr. Zhang(" Neptunus Holding ", ...
(Date:7/4/2015)... 2015 Añadir micro esferas ... primera línea para pacientes con cáncer colorrectal metastásico ... supervivencia libre de progresión en ese órgano ... resecable (mCRC) que se ha propagado sólo al ... libre de progresión (PFS) en el hígado desde ...
(Date:7/4/2015)... BARCELONA, Spain , July 4, 2015 /PRNewswire/ ... to first-line chemotherapy for patients with unresectable metastatic ... Progression-Free Survival in that organ Patients ... spread only to the liver experienced the greatest ... from the addition of SIR-Spheres Y-90 resin microspheres ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 2China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 3China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 4China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 5China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 6El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 2El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 3El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 4El Congreso Mundial del Cáncer Gastrointestinal presenta nuevos datos del estudio SIRFLOX 5New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 2New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 4
... CIVCO Medical Solutions is pleased to announce ... of Advanced Robotics and Workflow Solutions. Ramirez will ... Protura Robotic Patient Positioning System and RFSuite RFID ...   http://photos.prnewswire.com/prnh/20110419/AQ85801LOGO ) "CIVCO is a ...
... DALLAS, Sept. 30, 2011 CCS Medical today announced the ... Branch, Texas in the Dallas-Fort Worth Metroplex. CCS Medical has ... and is a market leader in distributing home healthcare products ... States. "Selecting Texas for our corporate relocation ...
Cached Medicine Technology:CIVCO Appoints Andres Ramirez Sales Director of Advanced Robotics and Workflow Solutions 2CCS Medical Relocating Corporate Headquarters to DFW Metroplex 2CCS Medical Relocating Corporate Headquarters to DFW Metroplex 3
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... care from nurses or midwives, yet there is a large gap between the ... midwifery research required to improve health outcomes and reduce unnecessary or ineffective treatments ...
(Date:7/6/2015)... ... ... Olive Fertility Centre is proud to announce that Olive medical director Dr. ... the department of Family Practice. , “This award is a real honour,” says Dr ... is changing so rapidly and we are also developing new models of patient-centred care ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... prevention in southern California, has partnered with Woodbridge Walk-In Urgent Care to offer ... stroke and other serious medical conditions. Screenings are affordable and accurate and run ...
(Date:7/6/2015)... , ... July 06, 2015 , ... Health care systems ... ability of the medical field to access and use this “Big Data” to improve ... President and Chief Executive Officer of the Mount Sinai Health System in New York ...
(Date:7/6/2015)... ... July 06, 2015 , ... In a split second, ... to reduce their risk of having a fracture through the bone health screenings conducted ... Day. , “We are participating because our residents need this information to remain independent ...
Breaking Medicine News(10 mins):Health News:Columbia Nursing Nairobi Summit: Setting a Clinical Research Agenda for Africa 2Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Woodbridge Walk-In Offers Affordable Early Detection Health Screenings Through Longevity 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 3Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 4Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 5Health News:National Bone Health Screening and Awareness Day 2
... experts issues a bold call to the Global Fund to ... salaries of health workers or else risk a situation in ... poor countries but there are no health professionals to deliver ... Global Fund," say Gorik Ooms (Medecins Sans Fronti?¨res, Belgium) and ...
... 'out-of-control' behavior that led to her stint in a rehab.// ... is blaming her parents for 'where she is at today ... of control' when her bizarre behavior landed her in the ... Page Six Friday, Jamie sided with Britney's manager Larry Rudolph, ...
... a Mediterranean country, is considered notoriously image-conscious. It may be ... clashing fiercely all the time. ,But the thirst ... ,Only that should explain why the Fist National Bank has ... ,Its website dubs the 'plastic surgery loans' as ...
... heart and headaches at Thomas Jefferson University Hospital are combining ... the cause// of some forms of migraine headaches. ... Center are enrolling participants in a blinded study to determine ... or flap that can allow blood to flow between the ...
... is the turn of beef products to be recalled on ... coli outbreak. Four of the five reporting// symptoms of the ... or Escherichia coli, is a common and ordinarily harmless bacteria, ... kidney failure, blindness, paralysis and sometimes death. ,E. ...
... monthly bleeding in women or menstruation may come as welcome relief ... it to be the symbol of fertility and would not like ... ,This has created a major uproar in the health world resulting ... pill called Lybrel. This pill is designed to eliminate periods as ...
Cached Medicine News:Health News:Health Expert’s Appeal to Global Fund to Fight HIV, TB and Malari 2Health News:Loans for Cosmetic Surgery in Lebanon 2Health News:Jefferson Researchers Want to Learn If Heart Defect 'at Heart' of Some Migraines 2Health News:E Coli Outbreak Forces Large-scale Recall of Beef Products 2Health News:Period Eliminating Pills 2
... ring electrodes feature a molded grip ... slider that moves smoothly and locks ... also feature ultraflexible, red-and-black, 61-cm (24-in) ... resistance of bend-relief protection at both ...
... bars made of silver/silver chloride have contacts ... easy separation into two individual tabs. For ... 17). Bar dimensions: 4 cm (1.6 in) ... 200-count package contains 50 individually sealed sets ...
... Video Camera System (NTSC)With Maxenon PowerPlus ... surgeon's eye view of any procedure. ... or digital files for later use. ... 8" to 36". Automatic Iris and ...
... and your patient warm, with the ... system.,Designed around the Coanda Effect, thousands ... air flow around your torso's blush ... the heat and stress induced environment ...
Medicine Products: